Traders should monitor the AACR presentations for signs of strong preclinical efficacy or safety differentiation in HMPL-A580, which could boost sentiment. However, absence of clinical data limits immediate upside; surufatinib combination updates may influence near-term positioning in pancreatic and GI cancers.
Price Chart
Executive Summary
HUTCHMED announced upcoming presentations of preclinical data for HMPL-A580, a first-in-class antibody-targeted therapy conjugate (ATTC), and updated clinical results for surufatinib combinations at the AACR 2026 meeting. The data highlight the novel mechanism and anti-tumor activity of HMPL-A580 in EGFR-expressing tumors and provide updates on ongoing trials in gastrointestinal and pancreatic cancers.
Key Facts
- Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR ATTC, will be presented at AACR 2026, showing potent and selective inhibition of tumor cell proliferation in EGFR-expressing models.
- HMPL-A580 demonstrated dose-dependent anti-tumor activity in xenograft models and favorable pharmacokinetics in monkeys, supporting its potential as a targeted therapy with improved safety over existing PAM inhibitors.
- Updated Phase Ib/II data for surufatinib plus sintilimab and capecitabine in metastatic small bowel and appendiceal carcinoma will be presented.
- Exploratory Phase II data on surufatinib combined with gemcitabine/nab-paclitaxel in pancreatic cancer following induction therapy will also be shared.
- No new clinical efficacy or safety data from human trials for HMPL-A580 were disclosed; all findings remain preclinical.
Financial Impact
Potential long-term value in oncology pipeline expansion, but no near-term revenue impact; HMPL-A580 remains preclinical
Risk Factors
- HMPL-A580 is in preclinical stage; clinical development risks include safety, tolerability, and lack of efficacy in humans.
- Combination therapies involving surufatinib rely on drugs not controlled by HUTCHMED, creating supply and regulatory dependency risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270617 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.31 (+1.42%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.31 (+18.07%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.31 (+13.21%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.31 (+32.87%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.31 (+25.09%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.31 (+33.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access